Dendritic cells are pivotal in detecting tumor presence and activating cytotoxic T cells that directly attack cancer cells. However, within the tumor microenvironment—a nutrient-deprived and hostile milieu—the energy metabolism of dendritic cells deteriorates progressively. The researchers discovered that this metabolic decline is primarily driven by impaired mitochondrial fitness, which essentially shifts dendritic cells into a low-energy state, diminishing their immunogenic function and enabling tumors to evade immune detection and destruction. This metabolic dysfunction represents a key barrier in mounting a durable antitumor immune response.

Using preclinical mouse models, the researchers introduced dendritic cells artificially programmed to maintain robust mitochondrial function into established tumors. This intervention restored the ability of dendritic cells to stimulate effective immune responses and significantly enhanced tumor control. These findings demonstrate that mitochondrial status is not merely a downstream consequence of cellular stress but a critical determinant of dendritic cell function with tangible therapeutic implications.

Dr. Hongbo Chi, chair of the Department of Immunology at St. Jude, emphasized the central discovery, stating that tumors actively reprogram mitochondrial metabolism within dendritic cells, curtailing their capacity to initiate immune attacks on the tumor itself. Restoring mitochondrial activity “rescued” dendritic cell capabilities, enabling them to re-engage and activate antitumor immunity. This insight highlights mitochondria as a viable target to overcome immune suppression imposed by tumors.

Immunotherapy, particularly immune checkpoint blockade, has revolutionized cancer treatment by unleashing the body’s own immune system to target tumors. Despite its success in certain cancers, many remain resistant. The team explored whether enhancing dendritic cell mitochondrial function could synergize with checkpoint inhibitors. Combination treatments in mice showed markedly improved outcomes compared to monotherapies, significantly slowing tumor growth and extending survival. This synergy suggests a promising avenue to bolster immunotherapy response rates where current therapies fall short.

Longitudinal studies also showed that mice receiving the combined dendritic cell and checkpoint blockade therapy successfully rejected new tumors introduced months later. This finding indicates that the intervention not only arrests existing tumor growth but also induces durable immune memory. Such lasting protection is a critical feature for preventing cancer recurrence, positioning mitochondrial activation of dendritic cells as a powerful immune memory adjuvant.

To unravel the molecular underpinnings, the researchers focused on mitochondrial-nuclear signaling pathways modulated within dendritic cells by the tumor environment. Two key proteins, OPA1 and NRF1, orchestrate this cross-talk and were found to be substantially downregulated in dendritic cells infiltrating tumors. This downregulation acts as a metabolic switch, falsely signaling an energetic crisis and triggering a shutdown of nonessential functions, including immunogenic activity, effectively disarming the immune response against cancer progression.

Co-first author Dr. Jiyeon Kim explained that the tumor microenvironment exerts direct regulatory control over dendritic cells via this mitochondrial reprogramming. Understanding this axis not only clarifies how tumors subvert immune surveillance but also opens new therapeutic opportunities to interrupt the process and restore potent immune function. Targeting the OPA1-NRF1 signaling cascade may hold promise for innovative immunometabolic interventions.

The comprehensive mechanistic insights gained in this study thus provide a foundation for the development of novel therapies that precisely rewire dendritic cell metabolism to boost anticancer immunity. Such therapies have the potential to complement existing treatments, overcoming resistance and improving patient outcomes in cancers previously refractory to immunotherapy.

Dr. Chi summarized the broader impact by emphasizing how these findings reaffirm dendritic cells’ critical role in cancer immunity. By illuminating how mitochondrial function is hijacked in the tumor microenvironment, this work pioneers a proof-of-principle approach to refine and enhance next-generation immunotherapies. Harnessing this strategy could transform the treatment landscape across a spectrum of malignancies.

This study was conducted by a multidisciplinary team of scientists including Nicole Chapman, Hao Shi, Yan Wang, Cliff Guy, Anil KC, Jia Li, Jordy Saravia, Gustavo Palacios, Sherri Rankin, Camenzind Robinson, Chuansheng Guo, Haoran Hu, and Xiaoxi Meng. Their collaborative efforts underscore the importance of integrated cellular and molecular immunology to unravel complex tumor-immune interactions.

Funding for the research was provided by grants from the National Institutes of Health and the American Lebanese Syrian Associated Charities (ALSAC), supporting St. Jude’s mission to pioneer innovative cancer therapies through rigorous scientific investigation.

Subject of Research: Cells

Article Title: Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity

News Publication Date: 2-Apr-2026

Web References:
DOI: 10.1126/science.adv6582

Image Credits: Courtesy of St. Jude Children’s Research Hospital

Keywords: Mitochondria, Mitochondrial function, Mitochondrial DNA, Mitochondrial proteins, Immunotherapy, Cancer

Tissue-resident macrophages are sentinel immune cells that reside permanently in tissues and play essential roles in maintaining homeostasis, detecting pathogens, and orchestrating inflammatory responses. Unlike their circulating counterparts, these macrophages must navigate the arduous landscape of localized inflammation, often persisting in hostile environments laden with reactive oxygen species and pro-inflammatory cytokines. The durability and functionality of these cells under chronic inflammatory conditions have long puzzled scientists, given the harsh milieu they endure.

Central to this newly discovered cellular resilience is the mitochondrion—a dynamic organelle well-known as the cell’s powerhouse but also a critical regulator of apoptosis and immune signaling. The study meticulously dissects how mitochondrial integrity and function are intricately tied to macrophage longevity in inflamed tissue. The authors employed a combination of sophisticated imaging, gene editing techniques, and metabolic assays to demonstrate that SerpinB2 is a key modulator ensuring mitochondrial health and, by extension, the survival of these innate immune cells.

SerpinB2, traditionally acknowledged as a serine protease inhibitor involved in inflammatory processes, emerges here as a mitochondrial guardian. The protein’s expression surges in chronically inflamed tissues, correlating strongly with enhanced mitochondrial respiration and reduced apoptotic signaling in macrophages. This suggests that SerpinB2 acts as a molecular shield, safeguarding mitochondria from dysfunction-induced cell death pathways, a phenomenon confirmed by experiments showing that SerpinB2 deficiency triggers mitochondrial collapse and macrophage apoptosis.

The researchers’ approach to elucidating this mechanism was exhaustive. By genetically ablating SerpinB2 in murine models, they observed a stark decrease in tissue macrophage populations during sustained inflammation. These macrophages exhibited diminished mitochondrial membrane potential, increased mitochondrial fragmentation, and a rise in reactive oxygen species, all hallmarks of compromised mitochondrial function. Single-cell RNA-sequencing further revealed a transcriptional shift toward pro-apoptotic gene programs, underscoring the catastrophic impact of SerpinB2 loss.

This discovery throws light on the intricate balance macrophages maintain between metabolic demands and survival signals within inflamed tissues. Mitochondria are not only energy suppliers but also pivotal nodes in signaling cascades that dictate cell fate. SerpinB2’s modulation of mitochondrial pathways effectively equips macrophages with the resilience required to sustain tissue surveillance amidst chronic inflammatory insults, highlighting a nuanced layer of immune regulation previously poorly understood.

Moreover, the study expanded its analysis into human pathological contexts, exploring tissue samples from patients with chronic inflammatory diseases such as rheumatoid arthritis and atherosclerosis. Remarkably, SerpinB2 expression patterns mirrored those observed in experimental models, reinforcing the translational relevance of the findings. The correlation between SerpinB2 levels and macrophage density in inflamed human tissues suggests potential for therapeutic targeting to bolster macrophage survival and tissue repair in chronic diseases.

Beyond immune cell survival, the implications of preserving mitochondrial function via SerpinB2 intersect with broader metabolic and inflammatory pathways. Mitochondrial dysfunction is increasingly recognized as a cornerstone in the pathophysiology of chronic diseases, including neurodegeneration, metabolic syndrome, and cancer. By identifying the regulatory axis of SerpinB2 and mitochondrial health in macrophages, this research opens up new avenues for modulating immune responses without compromising cellular vitality.

The researchers also delved into the molecular interactions underpinning SerpinB2’s mitochondrial protective effects. Biochemical assays revealed that SerpinB2 directly interacts with components of the mitochondrial permeability transition pore (mPTP), a critical regulator of mitochondrial-mediated apoptosis. This interaction appears to inhibit mPTP opening, thereby preventing mitochondrial depolarization and release of pro-apoptotic factors—a sophisticated mechanism ensuring macrophage endurance under chronic stress.

Notably, the study differentiated the effects of SerpinB2 from classical antioxidant pathways. Although reactive oxygen species generation was elevated in SerpinB2-deficient macrophages, the protective protein’s role extended beyond simple ROS scavenging. Instead, SerpinB2 functions as a sentinel modulating mitochondrial dynamics—fission and fusion events critical for maintaining mitochondrial network integrity, which is vital for cell survival and function.

The research team also explored potential therapeutic strategies. By artificially enhancing SerpinB2 expression in macrophages, both in vitro and in animal models, they demonstrated improved cell survival rates and functional maintenance in chronically inflamed tissues. This raises the exciting prospect of developing SerpinB2-based therapies or small molecules that can mimic its mitochondrial protective effects, offering novel treatment modalities for chronic inflammatory disorders.

Furthermore, these findings challenge the existing paradigms of macrophage plasticity. The metabolic adaptations facilitated by SerpinB2 suggest that mitochondrial function is not merely a background process but a decisive driver in determining macrophage phenotype and longevity. This reshapes how scientists perceive immune cell metabolism in the context of tissue microenvironments and disease progression.

In the broader landscape of immunology and cell biology, the elucidation of SerpinB2’s role adds a vital piece to the puzzle of immune homeostasis. It underscores the importance of metabolic regulation in immune cell fate decisions and highlights the potential for targeting mitochondrial pathways to fine-tune immune responses, especially in chronic inflammatory states where conventional anti-inflammatory drugs often fall short.

As chronic inflammation underlies a multitude of diseases affecting millions worldwide, understanding cellular survival mechanisms has profound clinical implications. This study not only provides a molecular blueprint for maintaining immune cell viability but also offers a promising scaffold for developing next-generation interventions aimed at resolving chronic inflammation without impairing host defense.

In conclusion, the work by Vasamsetti and colleagues propels the field forward by delineating a hitherto unrecognized mitochondrial safeguard mechanism mediated by SerpinB2. Their comprehensive characterization of this pathway enriches our comprehension of immune resilience and opens new therapeutic horizons. Future research expanding on these findings could transform the management of chronic inflammatory diseases, potentially leading to more effective and targeted therapies that bolster tissue-resident macrophage function at the mitochondrial level.

Subject of Research: Tissue-resident macrophage survival and mitochondrial function regulation by SerpinB2 in chronic inflammation.

Article Title: Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation.

Article References:
Vasamsetti, S.B., Sadaf, S., Uddin, M.A. et al. Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation. Nat Commun 17, 1493 (2026). https://doi.org/10.1038/s41467-026-69196-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-69196-4